Evidence map›Paper›PMID 42898724›Full record

ReviewMicrobiome research reports2026

Intratumoral microbiota and their emerging role in the tumor microenvironment.

Xianfeng Hui, Shihuan Ding, Ge Gao, Shuoxiang Gao, Jiaqi Tian, Shuochen Xu, Bingqi Yan, Rujing Zhang, Tiesuo Zhao, Hui Wang

Abstract readReview
In one paragraph

Review in Microbiome research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xianfeng HuiDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Shihuan DingDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Ge GaoHenan Key Laboratory of Immunology and Targeted Drug, Henan Medical University, Xinxiang 453003, Henan, China.
Shuoxiang GaoDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Jiaqi TianCollege of Medicine, Henan University, Kaifeng 475001, Henan, China.
Shuochen XuDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Bingqi YanDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Rujing ZhangDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Tiesuo ZhaoDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, Henan, China.
Hui WangHenan Key Laboratory of Immunology and Targeted Drug, Henan Medical University, Xinxiang 453003, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intratumoral microbiota, as an important component of the tumor microenvironment, have attracted increasing attention in recent years for their roles in tumor initiation, progression, and therapeutic regulation. Accumulating evidence indicates that low-abundance yet relatively stable microbial communities are present in a variety of solid tumors, exhibiting marked tumor-type specificity and spatial heterogeneity. Current studies suggest that intratumoral microorganisms contribute to tumor progression through multiple mechanisms, including activation of oncogenic signaling pathways, modulation of chronic inflammatory responses, remodeling of the immunosuppressive microenvironment, and regulation of metabolic reprogramming and drug responsiveness. Meanwhile, their bidirectional effects on chemotherapy, radiotherapy, targeted therapy, and immunotherapy highlight their potential roles in determining therapeutic sensitivity and the development of resistance. Despite existing challenges such as low microbial biomass, contamination control, and difficulties in functional validation, advances in spatial multi-omics and single-cell technologies are continuously enhancing the potential clinical value of intratumoral microbiota in tumor diagnosis, prognostic assessment, and precision therapy. This review summarizes the sources, colonization mechanisms, biological functions, roles in therapeutic modulation, and clinical applications of intratumoral microbiota, aiming to provide a theoretical basis for future research and clinical translation.

Indexed as

immune regulationMicroorganisms within tumorsprecision treatmenttreatment responsetumor microenvironment

Identifiers

PMID42898724
PMCPMC13678546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.